Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: ExposureDefinition: Therapeutic-dose anticoagulation with heparin - XML Representation

Raw xml | Download


<Group xmlns="http://hl7.org/fhir">
  <id value="291369"/>
  <meta>
    <versionId value="2"/>
    <lastUpdated value="2024-11-16T20:11:23.273Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-definition"/>
  </meta>
  <text>
    <status value="empty"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
  </text>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
    <valueContactDetail>
      <name value="Brian S. Alper"/>
    </valueContactDetail>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact">
    <valueRelatedArtifact>
      <type value="cite-as"/>
      <citation
                value="ExposureDefinition: Therapeutic-dose anticoagulation with heparin [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 291369. Revised 2024-11-16. Available at: https://fevir.net/resources/Group/291369. Computable resource at: https://fevir.net/resources/Group/291369."/>
    </valueRelatedArtifact>
  </extension>
  <url value="https://fevir.net/resources/Group/291369"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="urn:ietf:rfc:3986"/>
    <value value="https://fevir.net/FOI/291369"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <title
         value="ExposureDefinition: Therapeutic-dose anticoagulation with heparin"/>
  <status value="active"/>
  <publisher value="Computable Publishing LLC"/>
  <contact>
    <telecom>
      <system value="email"/>
      <value value="support@computablepublishing.com"/>
    </telecom>
  </contact>
  <description
               value="This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide."/>
  <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  <membership value="conceptual"/>
  <combinationMethod value="any-of"/>
  <characteristic>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="ATTACC investigational arm: Therapeutic anticoagulation for 14 days (or until hospital discharge or liberation from the need for supplemental oxygen, whichever comes first) with preference for low-molecular weight heparin (LMWH), or alternative unfractionated heparin (UFH). LMWH dosed according to patient weight and creatinine clearance according to local practice and policy. For UFH, suggested target of aPTT 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels."/>
    </valueCodeableConcept>
    <exclude value="false"/>
    <durationDuration>
      <value value="14"/>
      <comparator value="&lt;="/>
      <unit value="days"/>
      <system value="http://unitsofmeasure.org"/>
      <code value="d"/>
    </durationDuration>
    <timing>
      <contextCode>
        <text value="study enrollment"/>
      </contextCode>
      <offsetRange>
        <low>
          <value value="0"/>
          <unit value="days"/>
          <system value="http://unitsofmeasure.org"/>
          <code value="d"/>
        </low>
        <high>
          <value value="14"/>
          <unit value="days"/>
          <system value="http://unitsofmeasure.org"/>
          <code value="d"/>
        </high>
      </offsetRange>
      <text
            value="Up to 14 days or until hospital discharge or recovery (defined as liberation from supplemental oxygen&gt;24 hours, provided oxygen was required), whichever comes first."/>
    </timing>
  </characteristic>
  <characteristic>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="ACTIV-4a investigational arm: Low-molecular weight heparin (LMWH) dosed according to patient weight and creatinine clearance. For UFH, suggested target of anti-Xa of 0.3-0.7 IU/ml or aPTT 1.5 to 2.5 times the upper limit of normal."/>
    </valueCodeableConcept>
    <exclude value="false"/>
    <durationDuration>
      <value value="14"/>
      <comparator value="&lt;="/>
      <unit value="days"/>
      <system value="http://unitsofmeasure.org"/>
      <code value="d"/>
    </durationDuration>
    <timing>
      <contextCode>
        <text value="study enrollment"/>
      </contextCode>
      <offsetRange>
        <low>
          <value value="0"/>
          <unit value="days"/>
          <system value="http://unitsofmeasure.org"/>
          <code value="d"/>
        </low>
        <high>
          <value value="14"/>
          <unit value="days"/>
          <system value="http://unitsofmeasure.org"/>
          <code value="d"/>
        </high>
      </offsetRange>
      <text
            value="Up to 14 days or until hospital discharge, whichever comes first."/>
    </timing>
  </characteristic>
  <characteristic>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="REMAP-CAP investigational arm: Dosed according to local hospital policy, practice, and guidelines for treatment of venous thromboembolism. Low-molecular weight heparin (LMWH) dosed according to patient weight. For UFH, suggested target for aPTT of 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels."/>
    </valueCodeableConcept>
    <exclude value="false"/>
    <durationDuration>
      <value value="14"/>
      <comparator value="&lt;="/>
      <unit value="days"/>
      <system value="http://unitsofmeasure.org"/>
      <code value="d"/>
    </durationDuration>
    <timing>
      <contextCode>
        <text value="study enrollment"/>
      </contextCode>
      <offsetRange>
        <low>
          <value value="0"/>
          <unit value="days"/>
          <system value="http://unitsofmeasure.org"/>
          <code value="d"/>
        </low>
        <high>
          <value value="14"/>
          <unit value="days"/>
          <system value="http://unitsofmeasure.org"/>
          <code value="d"/>
        </high>
      </offsetRange>
      <text
            value="Up to 14 days or until hospital discharge, whichever comes first."/>
    </timing>
  </characteristic>
</Group>